News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Jill Feldman: Dosing studies are critical!
Photo taken from Jill Feldman/LinkedIn
May 9, 2024, 14:30

Jill Feldman: Dosing studies are critical!

Jill Feldman, Co-Founder of EGFR Resisters, shared a post on X:

“Dosing studies are critical!
OS and QOL both matter and pts/fam are the ONLY ones who can choose what matters most to THEM Amgen Oncology (and many others) please consider alternate doses while doing further studies
PhRMA, please push MED (minimal effective), NOT MTD.”

Read further.
Source: Jill Feldman/X

Amgen Oncology cancer EGFR Resisters Jill Feldman OncoDaily Oncology PhRMA
Special Coverage
Blog
Apr 21, 2025, 23:52
Carmen Monge-Montero: Rasika Bombatkar on a Surprising Side Effect of Cancer Treatment
Blog
Apr 21, 2025, 20:46
Luis E Raez Prepares for MATOS 2025 Lung Cancer KOL Retreat
Blog
Apr 21, 2025, 20:30
Dilyara Kaidarova Hosts Central Asian Lung Cancer Forum 2025
Blog
Apr 21, 2025, 20:11
Julien Vos to Present on Colon Cancer Survivorship at MASCC 2025
Insight
Apr 21, 2025, 19:55
CXCL8, Neutrophils, and Tumor Immunity: Insights by James P. Crowley
Blog
Apr 21, 2025, 19:34
Karin Manchester: When I was told I had leukaemia, I never thought I would still be here 20 years later - ICR
Blog
Apr 21, 2025, 19:12
European School of Oncology Shares New Oncopedia Module on Breast Cancer
Blog
Apr 21, 2025, 18:55
Julie Ince-Demetriou: National Breast Cancer Foundation is hiring science communications specialist
Blog
Apr 21, 2025, 18:19
Lung Cancer Consensus Statement is now officially endorsed by ICC
Blog
Apr 21, 2025, 18:00
Ajlan Al Zaki’s Inspiring Medical Journey Recognized by Alexis Geppner
Insight
Apr 21, 2025, 17:40
Nazik Hammad Publishes Framework on Women, Power, and Cancer in The Lancet
Blog
Apr 21, 2025, 17:35
Stephen Liu: Georgetown Cancer Institute is looking for a sarcoma specialist